COVID-19: Overview and Update

Michelle A. Barron, MD
Professor of Medicine
Division of Infectious Diseases
University of Colorado Denver
Medical Director, Infection Prevention and Control
UCHealth University of Colorado Hospital

June 2020
Situation Update – World – February 28, 2020

Total Confirmed: 83,867

Total Deaths: 2,867

Total Recovered: 36,686

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
Situation Update – World – September 10, 2020

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University

Global Cases: 28,054,276

Cases by Country/Region/Sovereignty:
- 6,395,904 US
- 4,465,863 India
- 4,238,446 Brazil
- 1,042,836 Russia
- 702,776 Peru
- 686,851 Colombia
- 652,364 Mexico
- 644,438 South Africa
- 554,143 Spain
- 524,198 Argentina

Global Deaths: 908,017

- 191,753 deaths in the US
- 129,522 deaths in Brazil
- 75,062 deaths in India
- 69,649 deaths in Mexico
- 41,697 deaths in the United Kingdom

Data sources: Full list, Downloadable database: GitHub, Feature Layer, Lancet Inf Dis Article: Here, Mobile Version: Here
Lead by JHU CSSE. Technical Support: Esri Living Atlas team and JHU APL. Financial

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
Increase in Cases in the US and CO

Cases of COVID-19 in Colorado by Date Reported to the State

https://covid19.colorado.gov/data/case-data
Testing and Impact of Colorado Shelter in Place Orders

Daily COVID-19 PCR Test Data From Clinical Laboratories With 7-Day Average Positivity

https://covid19.colorado.gov/data/case-data
Age-Adjusted COVID-19 Hospitalizations by Race and Ethnicity


- Non-Hispanic American Indian or Alaska Native: 221.2
- Non-Hispanic Black: 178.1
- Hispanic or Latino: 160.7
- Non-Hispanic Asian or Pacific Islander: 48.4
- Non-Hispanic White: 40.1

Future Prevalence of COVID-19

POSSIBLE SCENARIO 1
Peaks and Valleys

SCENARIO 2
Fall Peak

SCENARIO 3
Slow Burn

Modified from the Center for Infectious Disease Research and Policy
Future state of closures in Colorado

We would like to introduce a new dial that streamlines the process of opening/closing when counties qualify based on their metrics.

- This dial represents a matrix that will add simplicity and predictability to how we open -- or close -- based on virus transmission levels.
- It can be used by communities to implement locally-driven strategies to achieve the desired level.
- By increasing simplicity and predictability, we can give local communities another tool to make life amidst the pandemic more sustainable.
Locations

This map is representative but not comprehensive of clinical research sites across the United States. Sites will be added as warranted by the needs of the studies.
COVID-19 Vaccine Trials

- Moderna Therapeutics (co-sponsored with NIH)
  - Name: mRNA-1273
  - Mode of action: mRNA vaccine (mRNA create viral proteins that mimic SARS-CoV-2 and illicit immune response)
  - Study status: Phase 3, enrolling 30k subjects in US (UCH is a clinical site)

- Pfizer
  - Name: BNT162b2
  - Mode of action: mRNA vaccine
  - Study status: Phase 2/3, enrolling 30k people in US, Brazil, Argentina, and Germany

- University of Oxford (AstraZeneca)
  - Name: ChAdOx1 nCoV-19
  - Mode of action: adjuvant vaccine (SARS-CoV-2 spike protein inserted into Adenovirus vector)
  - Study status: Phase 3, enrolling 50k people in Brazil, UK, US, and South Africa (PVH is a site)
COVE Study: A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

- Phase 3, randomized, observer-blind, placebo controlled
- Primary goal: Evaluate the efficacy of mRNA-1273 to prevent COVID-19 disease compared to placebo
- 30,000 immunocompetent participants
- IM injection 100 µg mRNA-1273 (or placebo; 1:1) on Day 1 and Day 29
- 25-40% of participants will be ≥65 years old
- Primary efficacy outcome: Number of participants with a first occurrence of COVID-19 starting 14 days after second dose of mRNA-1273

https://clinicaltrials.gov/ct2/show/nct04470427
COVE Study Key Entry Criteria

• High risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19
• Healthy adults or adults with pre-existing medical conditions who are in stable condition
• No known history of SARS-CoV-2 infection
• No immunosuppressive or immunodeficient state (well controlled HIV allowed)
• Not participated in another interventional clinical study within 28 days
• Not received influenza vaccine in past 14 days or any other vaccines in the past 28 days
Site: Race Comparison

- **American Indian or Alaska Native**: 1
- **Asian**: 0
- **Black or African American**: 0
- **Hispanic or Latino**: 16
- **More than one race**: 2
- **Other**: 1
- **White**: 45

Legend:
- Green circle: Actual Enrollment
- Black circle: Expected Enrollment
COVID-19 Vaccine Distribution (when available)

- Will likely be distributed via CDPHE to either county public health departments and/or hospital systems
- GEEERC working group to determine prioritization and assignment of groups to Tiers
- Will not be mandated but will be encouraged
Questions?